Review





Similar Products

c16 paf  (MedChemExpress)
95
MedChemExpress c16 paf
C16 Paf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c16 paf/product/MedChemExpress
Average 95 stars, based on 1 article reviews
c16 paf - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
proprietary c16 sirna conjugate platform  (Alnylam Inc)
86
Alnylam Inc proprietary c16 sirna conjugate platform
(A) Unconjugated or <t>C16-modified</t> Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA <t>antibody.The</t> <t>C16-siRNA</t> demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Proprietary C16 Sirna Conjugate Platform, supplied by Alnylam Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proprietary c16 sirna conjugate platform/product/Alnylam Inc
Average 86 stars, based on 1 article reviews
proprietary c16 sirna conjugate platform - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
c16 peg 2000 ceramide  (Croda International Plc)
94
Croda International Plc c16 peg 2000 ceramide
(A) Unconjugated or <t>C16-modified</t> Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA <t>antibody.The</t> <t>C16-siRNA</t> demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
C16 Peg 2000 Ceramide, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c16 peg 2000 ceramide/product/Croda International Plc
Average 94 stars, based on 1 article reviews
c16 peg 2000 ceramide - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
c16  (Macklin Inc)
86
Macklin Inc c16
(A) Unconjugated or <t>C16-modified</t> Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA <t>antibody.The</t> <t>C16-siRNA</t> demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
C16, supplied by Macklin Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c16/product/Macklin Inc
Average 86 stars, based on 1 article reviews
c16 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
polyethylene glycol peg 2000 c16 ceramide conjugate  (Croda International Plc)
91
Croda International Plc polyethylene glycol peg 2000 c16 ceramide conjugate
(A) Unconjugated or <t>C16-modified</t> Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA <t>antibody.The</t> <t>C16-siRNA</t> demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Polyethylene Glycol Peg 2000 C16 Ceramide Conjugate, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyethylene glycol peg 2000 c16 ceramide conjugate/product/Croda International Plc
Average 91 stars, based on 1 article reviews
polyethylene glycol peg 2000 c16 ceramide conjugate - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
paf  (MedChemExpress)
95
MedChemExpress paf
(A) Unconjugated or <t>C16-modified</t> Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA <t>antibody.The</t> <t>C16-siRNA</t> demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Paf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/paf/product/MedChemExpress
Average 95 stars, based on 1 article reviews
paf - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
hexadecyl  (Croda International Plc)
95
Croda International Plc hexadecyl
(A) Unconjugated or <t>C16-modified</t> Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA <t>antibody.The</t> <t>C16-siRNA</t> demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Hexadecyl, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hexadecyl/product/Croda International Plc
Average 95 stars, based on 1 article reviews
hexadecyl - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
dipalmitoyl sn glycero 3 phospho  (Croda International Plc)
95
Croda International Plc dipalmitoyl sn glycero 3 phospho
(A) Unconjugated or <t>C16-modified</t> Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA <t>antibody.The</t> <t>C16-siRNA</t> demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Dipalmitoyl Sn Glycero 3 Phospho, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dipalmitoyl sn glycero 3 phospho/product/Croda International Plc
Average 95 stars, based on 1 article reviews
dipalmitoyl sn glycero 3 phospho - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
1 2 dierucoyl sn glycero 3phosphocholine  (Croda International Plc)
95
Croda International Plc 1 2 dierucoyl sn glycero 3phosphocholine
(A) Unconjugated or <t>C16-modified</t> Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA <t>antibody.The</t> <t>C16-siRNA</t> demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
1 2 Dierucoyl Sn Glycero 3phosphocholine, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/1 2 dierucoyl sn glycero 3phosphocholine/product/Croda International Plc
Average 95 stars, based on 1 article reviews
1 2 dierucoyl sn glycero 3phosphocholine - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

Image Search Results


(A) Unconjugated or C16-modified Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA antibody.The C16-siRNA demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journal: International Journal of Pharmaceutics: X

Article Title: Brain-targeted delivery of siRNA via non-viral delivery systems, the therapeutic strategy for Alzheimer's disease—Unveiling challenges and prospects

doi: 10.1016/j.ijpx.2026.100503

Figure Lengend Snippet: (A) Unconjugated or C16-modified Sod1-targeting siRNA was administered as a single intrathecal bolus injection to rats at 0.9 mg, and siRNA biodistribution was assessed in whole brain at 24 h post-dose using IHC with anti-siRNA antibody.The C16-siRNA demonstrated superior brain biodistribution compared to its unconjugated version after a single intrathecal injection in rats. (B) Robust neuronal and glial cell drug accumulation (magenta) in cerebral cortex (left panel). Dual IHC for the detection of siRNA and cell-type-specific targets in neurons (Map2), astrocytes (Gfap) and microglia (Iba1). (C) APP-targeting siRNA was administered as a single intrathecal bolus injection to cynomolgus monkeys at 60 mg, and, 3 months post-dose, tissue samples were analyzed for APP mRNA levels by RT–qPCR after 85 days. NHP, non-human primates; Images reproduced from Ref. . (D) Co-administration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations. Images reproduced from Ref. ( , ). (E) The dual-targeting divalent siRNA is highly programmable, enabling simultaneous modulation of two different disease-relevant gene pairs (e.g. Huntington's disease: MSH3 and HTT; Alzheimer's disease: APOE and JAK1) with similar potency to a mixture of single-targeting divalent siRNAs against each gene. Images reproduced from Ref. . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Early results from this phase I trial of ALN-APP ( NCT05231785 ) demonstrate that Alnylam's proprietary C16-siRNA conjugate platform has achieved the first human clinical transformation in CNS delivery and is the first clinical demonstration of RNA therapy silencing disease-causing genes in the human brain.

Techniques: Modification, Injection, Quantitative RT-PCR